person
Agnes J.
- Country
- The Netherlands
- Department
- Medical Oncology
Research Overview
assignment
11
Clinical Trials ·
- Adjuvant Pembrolizumab Versus Capecitabine or Olaparib in Patients with Early-Stage Triple-Negative Breast Cancer with Residual Disease Following Neoadjuvant Therapy
- Phase 3 Multicenter Randomized Study of Trastuzumab Deruxtecan vs. Trastuzumab Emtansine in High-Risk HER2-Positive Breast Cancer with Residual Disease
- Efficacy and Safety of Olaparib as Adjuvant Therapy in Germline BRCA1/2 Mutated High-Risk HER2-Negative Primary Breast Cancer: A Phase III Randomized Study
location_city
1
Research Sites
Data & Insights
medical_services
Primary Speciality
Main therapeutic area
handshake
Return Partnerships
Recurring site collaborations
183
Sites with multiple studies
Has run more than one trial at 183 of 417 partner sites.
Specializations
Advanced Breast Cancer Therapy
This investigator specializes in treating advanced and metastatic breast cancer, with particular focus on HER2-positive and hormone receptor-positive disease variants.
- Targeted HER2 Therapies
- Endocrine Therapy Combinations
- CDK4/6 Inhibition Strategies
Innovative Treatment Approaches
The investigator works with novel therapeutic approaches including antibody-drug conjugates and targeted molecular therapies for breast cancer treatment.
- Trastuzumab-based Treatments
- PARP Inhibitor Therapy
- Immunotherapy Combinations
Specialized Cancer Conditions
Research focus includes treatment of triple-negative breast cancer and management of vasomotor symptoms in cancer patients.
- BRCA-mutated Breast Cancer
- High-risk Stage III Disease
- Treatment-resistant Disease
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.